Condition: AML, Childhood · Aml · Acute Myeloid Leukemia, Pediatric · Sponsor: Washington University School of Medicine
This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
This description comes directly from the study's public registry record.
Thomas M Pfeiffer, M.D. · 314-273-2070 · pthomas@wustl.edu
Always discuss trial participation with your own doctor first.
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06158828